Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Aptose Biosciences ( (TSE:APS) ) just unveiled an update.
On June 20, 2025, Aptose Biosciences announced a new loan agreement with Hanmi Pharmaceutical for up to $8.5 million to advance the clinical development of tuspetinib in triplet therapy for AML. This agreement is considered a related-party transaction under Canadian securities laws, but Aptose is utilizing a financial hardship exemption. The ongoing TUSCANY triplet Phase 1/2 study has shown promising results in safety and efficacy, targeting various kinases while avoiding typical toxicities.
The most recent analyst rating on (TSE:APS) stock is a Buy with a C$60.00 price target. To see the full list of analyst forecasts on Aptose Biosciences stock, see the TSE:APS Stock Forecast page.
Spark’s Take on TSE:APS Stock
According to Spark, TipRanks’ AI Analyst, TSE:APS is a Underperform.
Aptose Biosciences faces significant financial distress with no revenue generation and substantial losses. The negative technical indicators and valuation metrics further highlight the stock’s weak position. However, recent corporate events provide a glimmer of hope with potential advancements in AML treatment and strategic partnerships, slightly mitigating the overall risks. The stock remains risky, requiring cautious optimism for future developments.
To see Spark’s full report on TSE:APS stock, click here.
More about Aptose Biosciences
Aptose Biosciences is a clinical-stage biotechnology company focused on developing precision medicines for oncology, particularly in hematology. Their pipeline includes small molecule cancer therapeutics designed to provide efficacy as single agents and enhance other anti-cancer therapies without overlapping toxicities. Their lead compound, tuspetinib, is an oral kinase inhibitor being developed for frontline triplet therapy in newly diagnosed acute myeloid leukemia (AML).
Average Trading Volume: 6,844
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$2.99M
See more insights into APS stock on TipRanks’ Stock Analysis page.